Bastidas et al found the herpes zoster vaccine (Shingrix) to be effective in patients who underwent autologous hematopoietic stem cell transplantation (HSCT). The phase III zoster efficacy trial tested a 2-dose course of the recombinant zoster vaccine in the HSC recipients. The study showed that during a median 21 months of follow-up, there was at least one herpes zoster case confirmed in 49 patients who received the vaccine and in 135 patients who received placebo (incidence rate ratio 0.32, 95% CI 0.22-0.44, P<0.001). Researchers conducted the study in 1846 patients undergoing HSCT (ZOE-HSCT) in 167 centres in 28 countries from July 2012 to February 2017. Those who had underwent HSCT in the past 50-70 days were involved in the study. Participants were randomized 1:1 to receive either the recombinant zoster vaccine or placebo in two 0.5 ml doses. The first dose was given 50-70 days following HSCT procedure and the second 1 to 2 months later. The findings showed that a 2-dose course of Shingrix could significantly reduce the incidence of herpes zoster over a median follow-up of 21 months.
Source: JAMA 9 July 2019;322(2):123-133. doi:10.1001/jama.2019.9053 https://jamanetwork.com/journals/jama/article-abstract/2737683